AI + mRNA full-stack independent R&D, complete loop from algorithm to product
AI + mRNA 全栈自研，从算法到产品的完整闭环
Advanced deep learning architecture combining CNN, LSTM, and large language models with molecular simulation for superior prediction accuracy
结合 CNN、LSTM、大语言模型与分子模拟的先进深度学习架构，实现优异的预测精度
| Technical Parameter | 技术参数 | TheraRNA | 澄实生物 | BioNTech |
|---|---|---|---|---|
| Sequencing Technology | 测序技术 | 3rd Gen Long-Read | 全长三代测序 | 2nd Gen Short-Read |
| Capture Method | 捕获 | Translatome | 翻译组 | WES + RNAseq |
| Antigen Prediction | 抗原预测 | MHC I + II | MHC I + II | MHC I |
| Patient Response | 患者响应率 | 80% (4/5) | 80% (4/5) | 50% (8/16) |
| Positive Epitope Rate | 表位阳性率 | 19.6% (11/56) | 19.6% (11/56) | 10.4% (25/240) |
Public IEDB data + ~1,000 internal tumor clinical datasets + Collaborative 1M+ immunopeptidome data
IEDB 公开数据 + 自有近千肿瘤临床数据 + 合作百万条免疫多肽组学数据
Ionizable cationic lipids with 4 delivery patents, validated against Moderna's SM-102 standard
自研可电离阳离子脂质，4 项递送体系专利，与莫德纳 SM-102 进行对标验证
Patent-protected sequence optimization and protein expression prediction using proprietary algorithms
专有算法驱动的受专利保护的序列优化与蛋白表达预测
Self-developed equipment, infrastructure, and processes for scalable mRNA vaccine production
自研生产设备、基础设施与工艺，实现 mRNA 疫苗规模化生产
R&D Cost per Product: ¥3-7M — approximately 1/3 of traditional technology pathway costs
单个产品研发成本：300-700 万 — 约为传统技术路线成本的 1/3
Temperature-stable formulation enabling global distribution at standard storage conditions
常温稳定制剂，实现全球常温物流与存储
Comprehensive patent protection and scientific publications supporting core technology platforms
为核心技术平台提供全面专利保护与科学验证
